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Abstract
Background: No reports exist on genotype-specific human papillomavirus (HPV) acquisi-
tion in girls after first sex in sub-Saharan Africa, despite high HPV prevalence and cer-
vical cancer incidence.
Methods:We followed 503HP-unvaccinated girls aged 15-16 years in Mwanza, Tanzania,
3-monthly for 18 months with interviews and self-administered vaginal swabs. Swabs
were tested for 13 higHRisk and 24 low-risk HPV genotypes. Incidence, clearance and
duration of overall HPV and genotype-specific infections were calculated and associated
factors evaluated.
Results: A total of 106 participants reported first sex prior to enrolment (N ¼ 29) or during
follow-up (N¼77). One was HIV-positive at the final visit. The remaining 105 girls contrib-
uted 323 adequate specimens. Incidence of any new HPV genotype was 225/100 person-
years (pys), and incidence of vaccine types HPV-6, -11, -16 and -18 were 12, 2, 2 and 7/100
pys, respectively. Reporting sex in the past 3 months and knowing the most recent sex-
ual partner for a longer period before sex were associated with HPV acquisition. Median
time from reported sexual debut to first HPVinfection was 5 months, and infection dur-
ation was 6 months.
Conclusion: This is the first description of HPV acquisition after first sex in sub-Saharan
Africa where the incidence of cervical cancer is amongst the highest in the world. HPV in-
cidence was very high after first sex, including some vaccine genotypes, and infection
duration was short. This very high HPV incidence may help explain high cervical cancer
rates, and supports recommendations that the HPV vaccine should be given to girls be-
fore first sex.
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Introduction
A number of closely related human papillomavirus (HPV)
genotypes are classified by the International Agency for
Research on Cancers (IARC) as oncogenic (Group I) or
probably oncogenic (Group IIA)1 and are commonly
referred to as ‘higHRisk’ (HR) HPVs. Persistent infection
(repeated detection over at least 6 months) with HR-HPV
is associated with ano-genital cancers in men and
women.2,3 Infection with HR-HPV genotypes is the pri-
mary cause of cervical cancer,4 and the highest age-stand-
ardized cervical cancer incidence and mortality worldwide
are seen in sub-Saharan Africa (SSA), along with some of
the highest HPV prevalences.5,6 Worldwide data have
shown that the highest prevalence is in women under 25
years old.6 From limited studies which have tested girls for
HPV before and after first sex, prevalence is high following
sexual debut.7–9
Current HPV vaccines are prophylactic, not thera-
peutic, and should be given before HPV acquisition.10
Knowledge of the rates and timing of HPV acquisition is
thus essential to inform HPV vaccination policy. To date,
no studies have documented genotype-specific HPV inci-
dence or overall HPV incidence in girls in SSA around the
time of sexual debut. A national HPV vaccination pro-
gramme for Tanzania, although in the planning stages, has
not yet commenced. In order to examine initial HPV infec-
tion and natural history, we enrolled 15- and 16-year-old
unvaccinated girls and followed them 3-monthly for 18
months in Mwanza, Tanzania.
Methods
Cohort enrolment
The cohort was enrolled as described previously.11 Briefly,
for preparation for an HPV vaccination trial, registration
lists of girls enrolled in government primary schools in
three districts of Mwanza region, northern Tanzania, were
collected in 2010.12 We enrolled girls who had been in
class 6 in 2010 in one of the 82 government schools not
randomly selected for vaccination. Additional enrolment
eligibility criteria included: being aged 15 or 16 years; self-
reporting never having had sex and currently not pregnant;
able to attend appointments; and willing to self-administer
a vaginal swab. Since the enrolment procedures involved
parental consent followed by participant assent and assess-
ment for eligibility, we elected to additionally include some
girls who reported sex in order to prevent stigmatization of
girls, since their virginity could potentially be inferred by
parents/others. We therefore randomly selected 26 schools
from which we enrolled the first girl who reported ever
having had sex, if her reported first sex was within the past
year.
Study procedures
The London School of Hygiene and Tropical Medicine
Ethics Committee and the Medical Research Coordinating
Committee, Tanzania, approved the study protocol in
2011. Consent procedures have been previously
described.11 Girls were enrolled between January and
August 2012, and followed 3-monthly for 18 months. At
each visit, girls had a face-to-face interview in Swahili with
a female study nurse using a structured paper question-
naire,11 and one nurse-assisted, self-administered vaginal
Dacron swab was obtained, irrespective of reported sex.
Girls who reported previous sex were offered a pregnancy
test and asked about symptoms of reproductive tract infec-
tions at every visit. Those reporting symptoms were exam-
ined in the research clinic and offered syndromic treatment
according to Tanzanian guidelines. At study completion,
girls were offered a rapid test for HIV with appropriate re-
ferral if positive. In this paper, we present data from girls
who reported passing sexual debut before or during the
study.
HPV detection and genotyping
Swabs were placed dry into cryotubes immediately after
collection, stored in cold boxes with ice-packs in the field,
Key Messages
• This is the first description of HPV acquisition after first sex in sub-Saharan Africa where the incidence of cervical
cancer is amongst the highest in the world.
• HPV incidence was very high after first sex, including of vaccine genotypes.
• Duration of HPV infection was short in these adolescent girls.
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submitted daily to the laboratory in Mwanza and stored at
-208C. They were shipped to the Catalan Institute of
Oncology, Barcelona, Spain, where HPV detection and
genotyping were performed using the Linear Array HPV
genotyping assay (Roche, USA). We used the updated HPV
types from the International Human Papillomavirus (HPV)
Reference Center (www.hpvcenter.se), and therefore
reclassified HPV55 as HPV44, HPV64 as HPV34, and
CP6108 as HPV89, and merged HPV-IS39 with HPV82.
Therefore, 36 HPV genotypes were detected (HPV6, -11,
-16, -18, -26, -31, -33, -34, -35, -39, -40, -42, -44, -45,
-51, -52, -53, -54, -56, -58, -59, -61, -62, -66, -67, -68,
-69, -70, -71, -72, -73, -81, -82, -83, -84, and -89). For this
study, we classified HPV genotypes in IARC groups I
(termed carcinogenic) and IIA (termed probably carcino-
genic) as HR; HPV -16, -18, -31, -33, -35, -39, -45, -51, -
52, -56, -58, -59, -68. All remaining genotypes were classi-
fied as LR.1 Methods for DNA extraction, amplification
and genotype detection were described previously.11
Specimens negative for b-globin amplification were
excluded, since vaginal sampling was assumed to be
unsuccessful.
Data management and statistical methods
Questionnaire data were double-entered into OpenClinica
LLC (Akaza Research, MA, USA), and analysed using
STATA V13.0 (StataCorp LP, TX, USA). Analyses were re-
stricted to girls whose reported sexual debut was before en-
rolment or during follow-up (’sexually active’). Girls who
were HIV-positive were excluded from all analyses.
Further detail on statistical methods can be found in the
Supplementary material (available as Supplementary data
at IJE online).
For each HPV genotype, the number of prevalent infec-
tions (present at enrolment among those sexually active at
entry), new infections (genotype not detected at enrolment
or before reported sexual debut) and cleared infections (a
new genotype that is no longer detected) was tabulated
among all sexually active girls. The genotype-specific
prevalence was estimated as the number of visits where the
genotype was detected, divided by the number of sexually
active visits.
Genotype-specific incidence was calculated; person-
years (pys) at risk were calculated from enrolment (among
girls whose reported sexual debut date was pre-enrolment)
or date of sexual debut (among girls who reported sexual
debut during follow-up). Kaplan-Meier methods were used
to estimate time from sexual debut to first HPV infection
among girls who reported sexual debut during follow-up
and who were HPV-DNA negative at all visits before re-
ported sexual debut (’HPV naı¨ve’).
The incidences of all new HPV, new HR-HPV and new
LR-HPV infections were calculated among: (i) all sexually
active girls; (ii) girls who reported sexual debut during fol-
low-up; and (iii) HPV-naı¨ve girls who reported sexual
debut during follow-up. The overall incidence rate and
95% confidence interval (CI) were estimated using random
effects Poisson regression to account for clustering of mul-
tiple infections within the same girl. Rate ratios (RR) for
factors associated with the incidence of new HPV infec-
tions among all sexually active girls were estimated using
random effects Poisson regression.
The genotype-specific clearance rate was calculated
among all sexually active girls who had acquired a new
genotype; pys at risk were calculated from the date of in-
fection (midway between the last negative and first positive
sample for the genotype). Kaplan-Meier methods were
used to estimate the median and mean duration of geno-
type-specific infections and the proportion of infections
cleared at 12 months. Cox regression with robust standard
errors was used to examine risk factors for clearance.
Results
Cohort screening, enrolment and follow-up
We located 1177 (75.7%) of 1555 potentially eligible girls
on the original school attendance lists. Of these, 801
(68.1%) met the age criteria, of whom 628 (78.4%) con-
sented to be screened (Supplementary Figure 1, available as
Supplementary data at IJE online). Of those screened, 503
(80.1%) were eligible and enrolled. Overall, 106 (21.1%)
participants reported first sex: 29 at enrolment, 77 during
follow-up. Among 29 girls whose reported date of first sex
was before enrolment, median time from sexual debut to
enrolment was 4.2 months (range 0.1-12.4). Among 106
girls reporting sex, 91 (85.8%) attended the final visit (18
months). The median [interquartile range (IQR)] follow-up
time was 17.8 (17.4-17.9) months.
At the final visit, 49 of 91 (53.8%) participants ac-
cepted HIV testing and 1 (1.1%) was positive. The remain-
ing 105 girls contributed 437 ‘sexually-active visits’ (visits
after the reported date of sexual debut, including the enrol-
ment visit) to the analysis; vaginal swabs were provided at
353 of these visits (80.8%), of which 323 (91.5%) were
adequate specimens and were genotyped.
At enrolment, 71/105 (67.6%) participants were aged
16 years and the others were aged 15. Nearly two-thirds
lived in rural areas (68, 64.8%);7 (6.7%) were in school;
and over half were neither working nor schooling (60,
57.1%). During the study, 71 (67.6%) reported ever hav-
ing cleansed inside their vagina, and only 1 girl reported
being circumcised.
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Table 1. HPV genotype prevalence, incidence, duration and clearance among 105 sexually active girls during follow-up
HPV type Prevalent (%)a New infections/
pys (rate/100 pys)b
New infections
that were cleared (%)c
N cleared/pys
(rate/100 pys)
Mean (median)
months duration
(Kaplan-Meier)d
HigHRisk genotypes
HPV16 0 1/44.0 (2.3) 0 0/0.1 (0) ‡
HPV18 0 3/44.6 (6.7) 1 (33%) 1/0.5 (211.7) 2.7 (2.7)
HPV31 0 2/43.6 (4.6) 1 (50%) 1/0.9 (113.8) 6.1 (6.1)
HPV33 0 2/44.5 (4.5) 1 (50%) 1/0.4 (268.6) 3.0 (3.0)
HPV35 0 2/44.5 (4.5) 1 (50%) 1/1.0 (99.5) 6.0* (4.9)
HPV39 1 (3%) 2/44.3 (4.5) 0 0/1.2 (0) 13.5* (†)
HPV45 0 1/43.1 (2.3) 1 (100%) 1/0.2 (403.6) ‡
HPV51 2 (7%) 4/41.7 (9.6) 3 (75%) 3/1.9 (158.7) 6.1 (6.1)
HPV52 0 1/44.3 (2.3) 1 (100%) 1/0.5 (198.5) ‡
HPV56 0 1/44.1 (2.3) 0 0/0.4 (0) ‡
HPV58 1 (3%) 6/42.1 (14.2) 0 0/1.8 (0) 13.2* (†)
HPV59 3 (10%) 2/42.7 (4.7) 1 (50%) 1/0.3 (289.9) 2.7 (2.7)
HPV68 0 1/44.9 (2.2) 0 0/0.1 (0) ‡
All HR infectionse 7 28 10 (36%) 10/9.4 (106.7) 6.9* (6.0)
Low-risk genotypes
HPV6 1 (3%) 5/41.0 (12.2) 2 (40%) 2/1.4 (146.8) 5.0 (6.1)
HPV11 0 1/45.1 (2.2) 0 0/0.2 (0) ‡
HPV26 0 0/45.5 (0) – – –
HPV34 0 1/45.4 (2.2) 0 (0%) 0/0.1 (0) ‡
HPV40 0 2/43.8 (4.6) 0 0/0.3 (0) 1.7* (†)
HPV42 0 3/41.9 (7.2) 1 (33%) 1/0.8 (133.3) 6.1 (6.1)
HPV44 0 4/43.8 (9.1) 1 (25%) 1/1.3 (78.4) 6.2* (4.9)
HPV53 0 2/42.7 (4.7) 1 (50%) 1/0.6 (180.4) 3.3* (3.0)
HPV54 1 (3%) 4/41.8 (9.6) 1 (25%) 1/1.4 (73.6) 6.1* (†)
HPV61 1 (3%) 0/45.0 (0.0) – – –
HPV62 0 3/43.6 (6.9) 1 (33%) 1/1.7 (59.2) 9.4* (2.7)
HPV66 1 (3%) 6/41.5 (14.4) 2 (33%) 2/3.2 (62.5) 11.3* (11.8)
HPV67 1 (3%) 1/44.6 (2.2) 1 (100%) 1/0.3 (299.4) ‡
HPV69 0 0/44.8 (0) – – –
HPV70 0 0/44.5 (0) – – –
HPV71 0 1/45.1 (2.2) 0 0/0.4 (0) ‡
HPV72 0 0/45.5 (0) – – –
HPV73 1 (3%) 4/43.1 (9.3) 1 (25%) 1/0.9 (117.6) 3.5* (2.7)
HPV81 0 1/45.0 (2.2) 0 0/0.1 (0) ‡
HPV82 0 0/45.4 (0) – – –
HPV83 0 3/40.7 (7.4) 1 (33%) 1/2.0 (50.6) 11.9* (†)
HPV84 2 (7%) 9/37.3 (24.1) 3 (33%) 3/3.1 (97.5) 6.0* (6.0)
HPV89 0 7/43.6 (16.1) 1 (14%) 1/1.8 (55.6) 7.0* (4.9)
All LR infectionse 8 57 16 (28%) 16/19.4 (82.6) 8.9* (6.1)
All HPV infections 156 85 26 (31%) 26/28.8 (90.4) 8.4* (6.1)
aPositive for that genotype at the enrolment visit, among 29 girls who were sexually active at enrolment.
bNew infection defined as first positive test for the specific HPV type, among those not infected at enrolment or before reported sexual debut. Girls with gaps >
180 days in observation time are censored at the most recent available HPV result before the gap.
cClearance defined as 2 consecutive samples negative for the specific genotype; denominator is total genotype-specific new infections.
dMean duration of new infections estimated using Kaplan-Meier methods restricted by the longest follow-up time (i.e. duration).
eTotal number of group (HR or LR)-specific infections among 105 girls.
*Mean duration of infection for the genotype is underestimated because the individual with the longest observed duration was censored.
†Median duration could not be estimated because survival curve does not drop below 50%.
‡One infection only, Kaplan-Meier survival function not estimated.
615 infections within 7 girls: 5 had at least one HR HPV genotype at enrolment, 5 had at least one LR HPV genotype at enrolment, 7 had any genotype at
enrolment.
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HPV prevalence and incidence
Of the 29 girls who reported ever having had sex at enrol-
ment, 7 (24.1%) had at least one prevalent HPV infection at
enrolment. A total of 28 new HR infections and 57 new LR
infections were detected during follow-up (Table 1). The
most common HR genotypes were HPV51 (5.0% of visits),
HPV58 (4.6%), HPV56 (4.0%) and HPV59 (4.0%)
(Figure 1).Genotype-specific incidence ranged from 2.2/100
person-years (pys) to 14.2/100 pys for each of the HR geno-
types, and 0 to 24.1/100 pys for each of the LR genotypes
(Table 1). The highest incidence rates (per 100 pys) of HR
types were for HPV58 (14.2), HPV51 (9.6) and HPV18 (6.7).
Among the 76 girls who reported first sex during fol-
low-up, 35 (46.1%) had at least one HPV infection
detected before the reported date of first sex. Among HPV-
naı¨ve girls, median time from reported sexual debut to
HPV infection was 4.9 months (Figure 2), and to first HR-
HPV was 9.3 months. Cumulative incidence of any HPV
infection at 6 months was 52.8%: 35.8% for HR and
34.7% for LR genotypes.
The overall incidence rate (per 100 pys) of new HPV
infections in sexually active girls (Table 2) was 225 (95%
CI: 166-305); HR-HPV incidence was 66 (95% CI: 45-95)
and LR-HPV was 157 (95% CI: 111-222). Among girls
who reported sexual debut during follow-up, the incidence
rate for new HPV infections and for new HR-HPV
infections were 209 (95% CI: 146-299) and 63 (95% CI:
40-99), respectively. Restricting to HPV-naı¨ve girls, these
were 193 (95% CI: 118-316) and 72 (95% CI: 42-122),
respectively. Overall, HPV was detected in 46% of ‘sexu-
ally active visits’ in all girls (Table 2).
Risk factors for incidence of new HPV infection
In the adjusted analysis (Table 3) there was evidence of
an association with: not being in a regular job or training
as compared with those with an occupation [adjusted (a)
RR¼ 1.95, 95% CI: 1.1-3.42], with the reporting of re-
cent sex (aRR 2.48, 95% CI: 1.40-4.37) and having
known the most recent partner for longer (aRR 3.15,
95% CI: 1.32-7.50). There was weak evidence of a
higher rate of new HPV infections among girls reporting
three or more partners compared with only one partner,
and weak evidence of a lower rate among girls who re-
ported vaginal cleansing (aRR 0.69, 95% CI: 0.43-1.10).
Figure 1. HPV genotype point prevalence (95% confidence interval), and number of infections at all visits after reported first sex in 105 adolescent
girls.
The HPV genotype-specific point prevalence was estimated as the number of visits where the genotype was detected, divided by the total number of
visits after the reported date of sexual debut, including the enrolment visit. Visits with missing vaginal samples, or with samples that were b-globin
negative, are excluded.
Figure 2. Time from sexual debut to first infection with any HPV, any HR
HPV or any LR HPV, among 41 girls who reported sexual debut during
follow-up and were HPV-naı¨ve at time of reported sexual debut.
Kaplan Meier curves are calculated separately for each HPV group.
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HPV duration and clearance
During follow-up, 33 girls acquired at least one new HPV
genotype and contributed 85 new infections to the geno-
type-specific duration and clearance analysis. In total, 26
of 85 (30.6%) new infections were cleared during follow-
up. Median duration of new HPV genotype-specific infec-
tions was 6.1 months. This was 6.0 and 6.1 months for
new HR and new LR-HPV genotypes, respectively. Overall
rate of clearance (per 100 pys) was 90.4 for any HPV geno-
type. After adjustment for age, there were no significant as-
sociations with any examined factors (Table 4).
Discussion
In this study, we demonstrate an extremely high incidence
of vaginal HPV infection after first sex in adolescent
Tanzanian girls. Acquisition was rapid in the initial
months after first reported sex, and over half of the girls
were positive for any HPV DNA in these first 6 months.
These findings support current recommendations that ado-
lescent girls should ideally be vaccinated before first sex.13
Few studies have examined HPV incidence in young
women after sexual debut. First acquisition of HPV (which
predominantly occurs in the months after first penetrative
sex) is a unique opportunity to document HPV genotypes to
which young women are exposed and which may then be-
come latent (and therefore un-detectable) until reactivation
later in life. Current molecular testing cannot differentiate
reactivation from first acquisition or re-infection and
therefore all studies of HPV incidence in sexually active
women can only record presumed incidence of HPV infec-
tions, since some apparent new infections may actually be
re-activations. HPV84, -83, -61, -66 and CP-108 were the
most common genotypes seen in our study. This is in con-
trast to global prevalence data in cytologically normal
women that have reported HPV16, -18, -52, -31 and -58 as
the most prevalent genotypes.6 In our study the incidence
rate of HPV vaccine genotypes was low, ranging between
2.4 and 13.6 per 100 pys for each of the HPV types covered
by the quadrivalent vaccine (HPV6, -11, -16 and -18); and
between 1.3 and 13.6 per 100 pys for each of the HPV types
covered by the new nonavalent vaccine (HPV6, -11, -16,
-18, -31, -33, -45, -52, -58).Incidence rates of HPV16 (2.3/
100 pys) and HPV-18 (6.7/100 pys) were lower relative to
other genotypes. Our data could be used in modelling stud-
ies to explore whether catch-up vaccination campaigns in
older girls (for example up to age 17 years) have additional
impact on cervical cancer incidence.
The overall HPV incidence in our study (187/1000 per-
son-months) was far higher than that reported in already
sexually active women. A cohort study of sexually active
women in Brazil, median age 33 years, reported an inci-
dence of 13.4/1000 person-months,14 and a study in
women in Canada, median age 21, reported an incidence
of 19/1000 person-months.15 Cumulative incidence has
been reported as 39-44% at 24 to 36 months after first sex
in Brazil and the USA,7,8,14 lower than 53% at the much
shorter follow-up period of 6 months in our study. Young
women are known to have a high incidence of infection,
Table 2. Incidence and point prevalence of HPV in adolescent girls who reported sex
Outcome All girls who reported
sexual debut before or
during the study (N5 105)
All girls who reported
sexual debut
during study (N5 76)a
Girls who reported sexual
debut during study and were
HPV-naı¨ve (N 5 41)b
Reported sexual
debut prior to
enrolment (N5 29)
Incidence
New infections/person-years (rate/100 person-years, 95% CI)c
All HPV 119/56.4 (225; 166-305) 62/30.1 (209; 146-299) 40/19.5 (193; 118-316) 57/26.3 (248; 144-425)
All HR HPV 37/56.4 (66; 45-95) 19/30.1 (63; 40-99) 14/19.5 (72; 42-122) 18/26.3 (71; 37-135)
All LR HPV 82/56.4 (157; 111-222) 43/30.1 (146; 97-218) 26/19.5 (127; 66-246) 39/26.3 (176; 95-327)
Prevalence
Total infections (number of visits with at least one infection/sexually active visits; % of all visits)d
All HPV 323 (148/323; 45.8%) 186 (87/172; 50.6%) 91 (40/106; 37.7%) 137 (61/151; 40.4%)
All HR HPV 108 (87/323; 26.9%) 57 (49/172; 28.5%) 32 (26/106; 24.5%) 51 (38/151; 25.2%)
All LR HPV 215 (118/323; 36.5%) 129 (70/172; 40.7%) 59 (29/106; 27.4%) 86 (48/151; 31.8%)
aHPV incidence among all girls who reported passing sexual debut during the study; includes 35 girls in whom HPV was detected before reported sexual debut
(infections before reported sexual debut do not contribute to the incidence estimate in this column, but girls are not excluded from the analysis).
bHPV incidence among 41 girls who reported passing sexual debut during the study and no HPV was detected before reported sexual debut.
cRate estimated from random effects Poisson regression: point estimates and 95% CI take into account correlation of repeated infections within girls. Girls
assumed to be continually at risk and can acquire > 1 infection at each visit. Observation time after gaps > 180 days contributes to the analysis, therefore total
number of infections is different from that in Table 1.
dTotal number of genotype-specific infections and number of visits where at least one genotype was detected at all visits after reported date of sexual debut,
including enrolment visit.
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Table 3. Association of selected potential risk/protective factorsa with any new HPV infection among 105 adolescent girls who
reported previous sex
Number of infectionsb/
person-years (rate/100 pys)
Crude RR (95% CI) Adjusted RR
(95% CI)c
Sociodemographic (enrolment)
Age at enrolment P ¼ 0.45
15 years 32/19.1 (189) 1
16 years 87/37.3 (244) 1.29 (0.67-2.47)
Religion P ¼ 0.83 P ¼ 0.83
Christian 99/49.2 (213) 1 1
Muslim 16/5.5 (333) 1.56 (0.59-4.12) 1.57 (0.60-4.16)
Other 4/1.7 (219) 1.16 (0.11-12.30) 1.07 (0.10-11.30)
Socioeconomic status score (tertiles) P ¼ 0.57 P ¼ 0.63
Low 58/25.5 (246) 1 1
Middle 33/20.3 (174) 0.70 (0.35-1.43) 0.72 (0.36-1.48)
High 28/10.6 (256) 1.04 (0.48-2.23) 1.03 (0.48-2.21)
Sociodemographic (time-varying)
Current residence P ¼ 0.80 P ¼ 0.53
Urban 50/20.7 (235) 1 1
Rural 65/34.6 (217) 0.92 (0.49-1.72) 0.82 (0.44-1.53)
Current occupation P ¼ 0.05 P 5 0.06
School 5/2.9 (164) 1.13 (0.30-4.26) 1.15 (0.30-4.36)
Work j vocational training 29/23.1 (144) 1 1
Not working 85/30.4 (283) 1.96 (1.12-3.43) 1.95 (1.11-3.42)
Currently married P ¼ 0.66 P ¼ 0.79
No 90/43.9 (217) 1 1
Yes 29/12.5 (248) 1.14 (0.63-2.09) 0.92 (0.50-1.70)
Alcohol since last visit P ¼ 0.42 P ¼ 0.48
No 116/55.2 (228) 1 1
Yes 3/1.2 (134) 0.59 (0.16-2.22) 0.62 (0.16-2.40)
Behavioural (time-varying)
Total partners ever P ¼ 0.09 P ¼ 0.09
1 86/43.1 (225) 1 1
2 16/10.0 (155) 0.69 (0.35-1.34) 0.77 (0.38-1.54)
3þ 16/2.5 (509) 2.26 (0.83-6.17) 2.76 (0.95-8.04)
Number of times had sex in past 3 months P ¼ 0.005 P 5 0.008
0 49/31.4 (159) 1 1
1 30/9.3 (400) 2.52 (1.44-4.42) 2.48 (1.40-4.37)
2þ 39/15.5 (257) 1.62 (0.95-2.77) 1.52 (0.88-2.63)
Most recent male sexual partner circumcised P ¼ 0.22 P ¼ 0.23
No 33/16.1 (182) 1 1
Yes 80/31.5 (263) 1.47 (0.79-2.72) 1.48 (0.77-2.85)
Don’t knowd 5/8.0 (109) – –
Most recent sexual partner was in a concurrent relationship P ¼ 0.06 P ¼ 0.25
No 53/31.1 (171) 1 1
Yes 12/2.7 (402) 2.37 (0.99-5.68) 1.83 (0.66-5.07)
Don’t knowd 53/21.7 (287) – –
Age difference of most recent partner P ¼ 0.11 P ¼ 0.10
 2 years 8/8.9 (82) 1 1
3–5 years 26/11.0 (215) 2.65 (1.03-6.83) 1. (1.04-6.45)
>5 years 35/13.1 (237) 2.64 (1.04-6.73) 2.33 (0.94-5.77)
Don’t knowd 49/22.6 (316) – –
Used condom at most recent sex P ¼ 0.93 P ¼ 0.90
No 105/46.5 (226) 1 1
Yes 13/9.1 (235) 1.04 (0.45-2.40) 0.95 (0.41-2.20)
(Continued)
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but the particularly high incidence in our study may be
driven by a high HPV prevalence in the male partners of
these young women.6,7,16–18 However, the incidence in our
cohort is higher than in other studies in young women in
East Africa: in sexually active women in Uganda (median
age 20 years), HPV incidence was 30.5/100 pys,19 and 74/
100 pys in women in Mwanza, Tanzania.17 The latter
study was performed in the same region, but participants
were older (median age 18), and all had reported previous
sex. These comparative findings support the suggestion
that incidence is highest around the time of first sex.
Comparing the incidence of individual genotypes in our
Tanzanian study with a study in women in the USA aged 16-
23 years, 5% of whom reported never having had sex20: in
our participants, HPV6, -11 and -18 incidences were 3-fold
higher. However, a lower rate was seen for HPV16 in our
study (2.3/100 pys) compared with the study in the USA (5.4/
100 pys). This is in keeping with findings that HPV-16 is less
common in SSA than in other regions including the USA.6,21
Not working was associated with increased HPV inci-
dence compared with being employed or in vocational
training. Girls not working may be at increased risk of
engaging in sex in exchange for gifts or money or of forced
sex, which are risk factors for HIV and other STIs,22 but
have not clearly been identified as risk factors for
HPV.23,24These behaviours were infrequently reported in
our study, although they have been described in local stud-
ies in older women.25 Knowing a partner for 6 or more
months before sex was associated with a more than 3-fold
risk of incident HPV compared with knowing a partner for
under 1 month. Girls may be more likely to be involved in
risky sex (i.e. without a condom) and therefore be at
increased risk of HPV,26 if a partner is well-known to
them. Contrary to that, reported condom use at most re-
cent sex was not associated with lower HPV incidence, al-
though numbers were small. Reported male partner
circumcision was similarly not associated with incident
HPV, in contrast to a large study in Uganda.27 However,
girls in our study may not have known whether their part-
ners were or were not circumcised.
Limitations of our study include the use of self-adminis-
tered swabs rather than clinician-collected cervical swabs.
We used self-administered swabs since speculum examin-
ation was undesirable in girls who had not passed sexual
debut. Over 90% were b-globin positive, indicating ad-
equate sampling.28 Further, a previous study in Uganda
demonstrated good HPV-genotype correlation in self-ad-
ministered and clinician-administered swabs.29
Unobserved intervals (without vaginal swab results) of
over 180 days were removed from the analysis. However,
Table 3. Continued
Number of infectionsb/
person-years (rate/100 pys)
Crude RR (95% CI) Adjusted RR
(95% CI)c
Does partner put saliva on penis P ¼ 0.58 P ¼ 0.26
No 78/33.5 (229) 1 1
Yes 7/1.7 (309) 1.34 (0.48-3.75) 1.87 (0.64-5.48)
Don’t knowd 2/0.5 (292) – –
Does partner use vaseline for sex P ¼ 0.007 P ¼ 0.17
No 77/35.7 (208) 1 1
Yes 10/1.1 (717) 3.44 (1.47-8.04) 2.06 (0.76-5.63)
Time had known most recent partner before first sex (with that partner) P ¼ 0.14 P5 0.03
< 1 month 26/16.1 (143) 1 1
1-6 months 64/28.0 (252) 1.76 (0.89-3.47) 1.76 (0.90-3.46)
6þ months 28/11.0 (314) 2.19 (0.92-5.20) 3.15 (1.32-7.50)
Cleansed vagina in past 3 monthse P ¼ 0.02 P ¼ 0.11
No 68/29.8 (300) 1 1
Yes 51/26.6 (169) 0.56 (0.35-0.90) 0.69 (0.43-1.10)
aPotential risk/protective factors were examined using a conceptual framework with three levels; age was considered an a priori confounder and included in all
models. Age-adjusted sociodemographic factors at enrolment were retained in a core model if associated with HPV infection at P < 0.10. Time-varying sociode-
mographic factors were added sequentially and retained if associated at P < 0.10. Time-varying behavioural factors were then added sequentially, and retained at
P < 0.10. All P-values presented in the table are from the likelihood ratio test.
bGirls are assumed to be continually at risk and can acquire > 1 infection at each visit. Observation time after gaps > 180 days contributes to the analysis;
therefore, the total number of infections (119) is different from that in Table 1.
cSociodemographic factors at enrolment adjusted for age (a priori). Time-varying sociodemographic factors adjusted for age (a priori) and all independent soci-
odemographic predictors of HPV infection (at P < 0.1) (occupation). Behavioural factors adjusted for age, occupation and all independent behavioural predictors
of HPV infection (number of times had sex in past 3 months and time knew most recent partner before sex (variables in bold).
d‘Don’t know’ responses considered missing data and not included in analysis.
eVaginal cleansing is cleaning inside the vagina with water, soap or other products using fingers or a cloth.
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Table 4. Clearance of new HPV infectionsa and associated factors among girls who reported having had sex at any time during
follow-up (unit of analysis is the infection)
Number cleared/
person-years (rate/100 pys)
Crude HR (95% CI) Adjusted HR (95% CI)
Sociodemographic (enrolment)
Age at enrolment P ¼ 0.03
15 years 8/6.1 (132.2) 1
16 years 18/22.7 (79.3) 0.09 (0.01-0.74)
Religion P ¼ 0.08 P ¼ 0.21
Christian 25/23.1 (108.3) 1 1
Muslim 1/4.8 (20.8) 0.39 (0.13-1.13) 0.53 (0.20-1.43)
Other 0/0.9 (0.0) – –
Socioeconomic status score (tertiles) P ¼ 0.10 P ¼ 0.12
Low 16/15.3 (104.6) 1 1
Middle 7/8.0 (87.6) 0.81 (0.22-3.02) 0.73 (0.37-1.45)
High 3/5.5 (54.9) 0.35 (0.13-0.93) 0.40 (0.14-1.09)
Sociodemographic (time-varying)
Current residence P ¼ 0.10 P ¼ 0.24
Urban 13/15.2 (85.4) 1 1
Rural 13/12.9 (101.0) 2.23 (0.85-5.85) 0.44 (0.11-1.71)
Current occupation P ¼ 0.88 P ¼ 0.56
School 6/7.8 (77.0) 1 1
Work j vocational training 0/0.1 (0.0) – –
Not working 20/20.8 (96.0) 0.90 (0.24-3.38) 1.55 (0.34-7.09)
Currently married P ¼ 0.25 P ¼ 0.46
No 21/23.8 (88.3) 1 1
Yes 5/5.0 (100.3) 0.44 (0.11-1.78) 0.60 (0.15-2.33)
Alcohol since most recent visit P¼0.35 P ¼ 0.35
No 24/27.5 (87.2) 1 1
Yes 2/1.2 (164.0) 2.45 (0.37–16.28) 2.45 (0.37-16.28)
Behavioural (time-varying)
Total partners ever P ¼ 0.58 P ¼ 0.16
1 18/17.6 (102.6) 1 1
2 4/5.4 (73.8) 0.84 (0.17-4.05) 0.26 (0.04-1.53)
3þ 4/5.7 (70.7) 0.60 (0.23-1.57) 0.84 (0.35-2.01)
Number of times had sex in the past 3 months P ¼ 0.14 P¼0.14
0 13/11.0 (118.4) 1 1
1 0/6.2 (0.0) – –
2þ 13/11.5 (112.7) 0.21 (0.02-1.69) 0.21 (0.02-1.69)
Most recent male sexual partner was circumcised P ¼ 0.06 P ¼ 0.18
No 15/13.7 (109.7) 1 1
Yes 11/14.4 (76.3) 0.38 (0.14-1.04) 0.56 (0.24-1.30)
Don’t knowb 0/0.5 (0.0) – –
Most recent sexual partner was in concurrent relationship
No 17/18.2 (93.3) – –
Yes 0/1.6 (0.0) – –
Don’t knowb 9/8.8 (102.1) – –
Used condom at last sex
No 26/26.9 (96.8) – –
Yes 0/1.8 (0.0) – –
Partner put saliva on penis P ¼ 0.75 P ¼ 0.75
No 18/22.0 (81.8) 1 1
Yes 3/2.0 (150.7) 0.88 (0.40-1.92) 0.88 (0.40-1.92)
Don’t knowb – – –
(Continued)
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sensitivity analyses, where girls were assumed to be unin-
fected with a new genotype during those intervals, gave
similar results [incidence among all ‘sexually active’ girls
was 158/100 pys, (95% CI: 123–203)]. Samples negative
or missing for a given genotype, but which had been taken
between two samples positive for that genotype, were clas-
sified as positive since studies describing long-term persist-
ence have demonstrated sporadic detection of the same
genotype early in the course of a persistent infection.30 We
excluded one girl who was HIV-positive at study comple-
tion, since HPV incidence is higher with HIV infection.31,32
Only 46% of participants attending the final visit accepted
an HIV test; therefore HIV-positive girls may have been
included in the analysis. However, national estimates indi-
cate a very low HIV prevalence in 15-19-year-old girls in
Tanzania (1.3%).33
Median time from first reported sex to acquisition of any
HPV was 5 months. This is longer than 2.4 months reported
in college students in the USA tested 3-monthly.34 Differences
in the types of relationships formed (marriage vs casual sex
partner), recent sex and condom use may explain these differ-
ences, since some of these have been identified as risk factors
for acquisition in our or other studies.26,35 Reporting bias
may have influenced accurate assessment of these risks: par-
ticipants in our study may have been less willing to report sex
and had less accurate recall of dates of sex compared with
women in the USA study. The median duration of infection
in our study was shorter (6 months) than in previous studies
(reported range 8-31 months14,15,36). This may be an under-
estimate since the duration of follow-up was limited com-
pared with these previous studies, and was dependent on the
point at which girls reported sexual debut.14,15,36 Clearance
events may have been falsely observed through lack of detec-
tion of HPV due to self-sampling. As discussed earlier, the
presence of b-globin was considered necessary to ensure ad-
equate vaginal sampling and will have reduced this risk. A
short duration of infection could be due to cervico-vaginal
immune activation in Tanzanian girls, which has been shown
to be higher in STI- and HIV-uninfected young women in
Kenya compared with the USA.37 High levels of endocervical
T lymphocytes identified in those women in Kenya could
have mediated HPV clearance.37 Finally, higher cervical HPV
viral load, age over 30 years, being HIV-positive and having a
high number of sex partners were associated with lower HPV
clearance in women in Uganda.32 We identified no associ-
ations with HPV clearance, potentially because our cohort
displayed little variation in age or number of sex partners,
and girls were either HIV-negative or of unknown HIV
status.
We report a rapid acquisition of HPV infection, extremely
high incidence and rapid clearance in young women after
their first reported sex. This study was carried out in a region
with one of the highest incidences of cervical cancer in the
world, and our findings may help to explain these high rates
of cervical cancer and the high HPV prevalence observed in
East Africa6 and support the current recommendation that
HPV vaccination should be given to girls before their first
sex.38
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